Thus, further clinical studies, preferably with more sophisticated measurements, in cohorts carefully matched by age, BMI and disease, will be required to fully explore the usefulness of MNA as a biomarker for insulin resistance and to assess its value beyond existing markers (e.g. high-sensitivity C-reactive protein or HbA1c). This evidence concerns the gene CRP and Insulin resistance.